SNDK
Sandisk Corporation
SNDK's fundamentals are strong: revenue more than tripled and its operating margin went from −19% to 72%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SURG
SurgePays, Inc.
There isn't enough reported data to score SURG yet.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
SURG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
SURG's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK's PE is 7.5x, but its earnings don't support one, so it isn't a reliable read right now.
SURG PE Valuation
SURG has no meaningful PE right now: it lost money over the past year.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
SNDK has the edge over SURG on the outlook, with more favorable revenue expectations.
SURG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SURG's losses to shrink, with revenue holding steady.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over SURG in the latest year-over-year earnings comparison.
SURG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$1.02 |
| Q1 2026 | -$1.93 | +$0.91 |
| Q4 2025 | -$1.80 | +$0.59 |
| Q3 2025 | -$2.19 | -$1.05 |
| Q2 2025 | -$2.54 | -3275% |
| Q1 2025 | -$2.84 | -349% |
| Q4 2024 | -$2.39 | -273% |
| Q3 2024 | -$1.14 | -179% |
SURG is still losing money, but far less than before: $1.52 per share over the past year, against $5.50 at its worst in early 2021.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK has the edge over SURG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over SURG on profitability, with a higher operating margin.
SURG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.2M | +41% |
| Q1 2026 | $16M | +51% |
| Q4 2025 | $16.2M | +69% |
| Q3 2025 | $18.7M | +292% |
| Q2 2025 | $11.5M | -24% |
| Q1 2025 | $10.6M | -66% |
| Q4 2024 | $9.6M | -70% |
| Q3 2024 | $4.8M | -86% |
SURG's revenue is recovering but still below its 2022 peak: $16M last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | +80 points |
| Q1 2026 | -70% | +1.6 points |
| Q4 2025 | -79% | +113 points |
| Q3 2025 | -37% | +262 points |
| Q2 2025 | -59% | +13 points |
| Q1 2025 | -72% | -77 points |
| Q4 2024 | -192% | -194 points |
| Q3 2024 | -299% | -320 points |
SURG's operating margin was 21% last quarter, up 80 points from the same quarter a year ago, near the top of its range since 2019.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the stronger cash trend. Its trailing FCF is up 762% versus its history, compared with SURG at down 63%.
SURG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$3.5M |
| Q1 2026 | -$4.6M | +$2.4M |
| Q3 2025 | -$4.6M | +$8.7M |
| Q2 2025 | -$6.1M | -$2M |
| Q1 2025 | -$7M | -272% |
| Q4 2022 | $4.7M | +$12.9M |
| Q3 2022 | -$801.2K | +$1.5M |
| Q2 2022 | $175.5K | +$1.6M |
SURG has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has the edge over SURG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
SURG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.4% | +2.2M shares |
| 1 year | +29% | +5.9M shares |
| 3 years | +109% | +13.5M shares |
| 5 years | +1122% | +23.8M shares |
SURG has 26M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has more cash than debt.
SURG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -2.2x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.3x | Net Cash |
| Q2 2023 | 0.0x | Very low |
| Q1 2023 | -0.3x | Net Cash |
| Q4 2022 | 0.4x | Very low |
SURG has more cash than debt.
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
SURG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 13.7 | Oversold |
SURG's weekly RSI is 32 (neutral) and its Stochastic is 14 (oversold).
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK is trading at 7.5x earnings, a 73% discount to the Technology sector's median of 28x, though its earnings don't support one.
SURG PE vs Technology Sector
| Metric | SURG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SURG has no meaningful PE right now: it lost money over the past year.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SURG has stronger trend alignment. SNDK is above 0 of 3 weekly averages versus SURG above 1 of 5.
SURG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.14 | 0% above |
| 20 week MA | $0.21 | 33% below |
| 50 week MA | $0.65 | 78% below |
| 100 week MA | $1.50 | 91% below |
| 200 week MA | $3.02 | 95% below |
SURG is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over SURG on returns for 2026, with the stronger performance.
SURG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $6.00 | -59% |
| 2021 | $6.00 | $2.31 | -62% |
| 2022 | $2.31 | $6.29 | +172% |
| 2023 | $6.29 | $6.45 | +2.5% |
| 2024 | $6.45 | $1.83 | -72% |
| 2025 | $1.83 | $1.68 | -8.2% |
| 2026 YTD | $1.68 | $0.14 | -92% |
SURG's yearly returns have swung widely, from +172% in 2022 to −72% in 2024. It's down 92% so far in 2026.